PF-Atlas › Clinical Trials › NCT06081621
A Clinical Study to Evaluate the Efficacy and Safety of REGEND001 Cell Therapy on Idiopathic Pulmonary Fibrosis
REGEND001 · Phase 2
Registry ID
NCT06081621
Phase
Phase 2
Status
Completed
Drug / intervention
REGEND001
Sponsor
Regend Therapeutics
Start
2023-12-11
Enrollment
23
Locations
4
About this trial
Idiopathic pulmonary fibrosis (IPF) is a serious chronic (long term) disease with injury of lung tissues. REGEND001 is a cell therapy product, made from bronchial basal cells with ability to regenerate lung tissue, is promising to IPF treatment. This is a multi-center, randomized, double-blinded, parallel and placebo-controlled phase II clinical study to evaluate the efficacy and safety of REGEND001 in IPF patients.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT06081621 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.